Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
about
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza VaccinesBalancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza InfectionDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadUniversal immunity to influenza must outwit immune evasionBroadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.Diet-induced obese mice exhibit altered heterologous immunity during a secondary 2009 pandemic H1N1 infectionA GFP-tagged nucleoprotein-based aggregation assay for anti-influenza drug discovery and antibody development.MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 virusesIL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protectionVaccinia-based influenza vaccine overcomes previously induced immunodominance hierarchy for heterosubtypic protection.Primary and long-term B-cell responses in the upper airway and lung after influenza A virus infection.The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.Influenza vaccines: a moving interdisciplinary field.H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Preexisting Antibody-Dependent Cellular Cytotoxicity-Activating Antibody Responses Are Stable Longitudinally and Cross-reactive Responses Are Not Boosted by Recent Influenza Exposure.Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease.Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans.Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designHigh titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceSubsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice.Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence.Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful.Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in miceAntiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 PandemicProlonged antigen presentation by immune complex-binding dendritic cells programs the proliferative capacity of memory CD8 T cells.Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice.Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.The pathogenesis of Rift Valley fever.Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliA bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses
P2860
Q26744622-111CCC65-E2EA-4D56-A60B-9EEFA776EC92Q26767517-BF55B7F3-0212-47AC-9B10-BDD0E4DA9999Q26783897-4E7D83D3-BE81-403E-8952-8164453B5403Q26991896-1E03463A-F9D1-41BD-8B5A-0DF957FE856DQ30223058-9196C70B-0FB2-49F7-B96D-A67F458D3748Q30352501-573FCFEF-1D64-4DBC-95EF-11FB10292536Q30352981-68EC6680-C44D-43EF-9689-4180EF807A45Q30358935-717AE59F-79F7-4057-96FB-6D76697A4FA8Q30361079-C68CF518-BF4E-491E-B331-454F2413839AQ30362529-48185AAB-E0FB-485B-B6D3-44520A9460D0Q30362668-C394905C-A7FC-4C65-9C1D-0F09B4B4CC25Q30365366-5579ED1B-EE55-4278-8CB0-FA43508F1559Q30367695-CBC8FED0-3E31-4A54-B6FB-4D5FE328BF14Q30371297-52AA21DA-DB48-454F-8756-F191DBF1C009Q30391515-AABD14D2-B355-4252-86B0-0AEDD93D15BCQ30395259-18D9E9B3-E286-48E6-9EA4-7D69D6832D19Q30397362-9CF0D7FE-E9D9-4EED-B187-ED1449BD802CQ30400230-22654CB2-94D4-444B-9335-315E28A1443CQ30400347-72D23466-2697-474C-BB13-2AA17D10C419Q30403507-3FB73E5A-7C92-480B-B858-382A2DA29B69Q30405211-C9939FF5-94FE-46F4-807D-6A61DA8586ABQ30410126-7D1B7C17-1C99-4008-9623-5E3BB3CAED34Q30416502-BEF31DCC-5CE5-443E-811A-296137998D46Q30416598-A954FE5B-DB7D-4058-9815-5DC1C59C66EFQ30420397-37A74221-43BC-48F9-9D79-D3BFBA40668CQ30425194-8D502456-A747-4673-90E6-D749D48AD602Q30429302-FE1C5AC7-F4C3-4A07-AFC5-21C7E0DAEBF7Q30429719-72691A6C-546D-4F84-ADB5-DED13FD9F720Q30431078-12C947CA-62ED-4BE6-BAC7-F7143674A87CQ33604567-F92C9D8B-8D70-432C-87F1-04D32A431F5EQ33867299-B4FD9568-FF68-4741-8E9B-6F89CF741632Q33904286-F628DB52-330E-4EAC-AFA9-493860DFC307Q33964275-D620AEAD-005C-42C4-A42A-7B23056677CFQ34031858-8FCA06F0-CEBB-4B11-9818-7DED2F9C9914Q34070683-FDDCA34A-887B-42FE-B616-07EB34230EC0Q34191969-330F0114-5660-4953-A8A2-1FF8918A30A1Q34533990-DFC2E1E9-83BE-46F5-94A0-850E3D3C6197Q34594671-472E18D5-B6AE-43C1-B919-688335D89EDBQ34629133-31ECDF28-70E1-40B4-92FE-BC2AF3F430C2Q34634852-81E44B36-67F4-454A-940F-57D7F68BF00B
P2860
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@ast
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@en
type
label
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@ast
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@en
prefLabel
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@ast
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@en
P2093
P2860
P356
P1476
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
@en
P2093
Amy Moquin
Denise A Kaminski
Frances E Lund
Ho-Tak Lam
Laura Haynes
Mark W LaMere
Troy D Randall
P2860
P304
P356
10.4049/JIMMUNOL.1003057
P407
P577
2011-02-25T00:00:00Z